GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference
Topics/Gallbladder and Pancreas/Native Hawaiian pancreatic cancer disparity study
71

Native Hawaiian pancreatic cancer disparity study

Clinical knowledge base written and curated by GastroAGI Team from primary medical literatureLast updated July 1, 2025

The study on pancreatic cancer disparities among Native Hawaiians, conducted as part of the Multiethnic Cohort Study, revealed significant findings about the heightened risk faced by this population compared to White individuals. Below is a detailed summary of the study and its findings:

Key Findings:

  1. Elevated Risk of Pancreatic Cancer:
  • Native Hawaiians were found to have a 71% higher risk of pancreatic cancer compared to White individuals, even after adjusting for established risk factors such as diabetes, obesity, smoking, alcohol use, and family history of cancer.
  • The incidence rates of pancreatic cancer were nearly double in Native Hawaiians (80.2 per 100,000 person-years) compared to Whites (44.6 per 100,000 person-years).
  1. Gender-Specific Risk:
  • The elevated risk persisted across both sexes:
  • Men: Hazard Ratio (HR) of 1.54.
  • Women: Hazard Ratio (HR) of 1.85.
  • This indicates that Native Hawaiian women face an even higher relative risk compared to White women.
  1. Impact of Comorbidities:
  • Risk of pancreatic cancer increased with the number of comorbidities (e.g., diabetes, obesity, smoking, alcohol use, or family history of cancer).
  • Native Hawaiian men with two or more risk factors had a fivefold greater risk compared to White men without any risk factors (HR 5.17).
  1. Diabetes as a Key Risk Factor:
  • Among Native Hawaiian men, diabetes was particularly impactful, tripling the risk of pancreatic cancer.
  1. Genetic and Environmental Contributions:
  • Genetic analyses suggested that the elevated risk in Native Hawaiians was independent of polygenic risk scores, indicating that other biological or environmental factors may be contributing to the disparity.

Implications:

The study concluded that the disproportionate burden of pancreatic cancer in Native Hawaiians likely stems from the higher prevalence and cumulative effect of risk factors in this population, particularly among men. This highlights the need for targeted interventions to address these disparities.

Recommendations:

  1. Targeted Prevention Strategies:
  • Developing culturally tailored prevention strategies to address modifiable risk factors such as diabetes, obesity, smoking, and alcohol use.
  1. Risk-Factor Modification:
  • Aggressive efforts to manage and reduce risk factors in high-risk Native Hawaiian populations.
  1. Exploration of Screening:
  • Researchers emphasized the potential benefits of exploring pancreatic cancer screening for high-risk Native Hawaiian individuals, given their elevated risk.
  1. Further Research:
  • Additional genetic and longitudinal studies are needed to better understand the mechanisms driving these disparities and to identify other potential contributors, whether biological, environmental, or social.

Conclusion:

The findings underscore the urgent need to address the unique health challenges faced by Native Hawaiians, particularly in the context of pancreatic cancer. By focusing on prevention, early detection, and further research, health disparities in this population can be better understood and mitigated.

Related Q&A

01

Pancreatic Cancer Early Detection: From High-Risk Surveillance to AI and Liquid Biopsy: RadioGraphics | October 2026

What Does the Review Highlight? This comprehensive review examines current pancreatic cancer screening strategies and emerging technologies for detecting pancreatic ductal adenocarcinoma (PDAC) at a potentially curable stage....

02

Liquid Biopsy Could Accelerate Precision Oncology in Advanced Biliary Tract Cancer: Clinical Cancer Research | October 2026

What Did the Study Find? This study evaluated ctDNA next-generation sequencing (NGS) as an alternative to tissue profiling in advanced biliary tract cancer (aBTC), addressing a major practical...

03

High-Risk Pancreatic Surveillance: Does the Germline Mutation Matter Once an IPMN Appears?: JAMA Network | September 2026

What Did the Study Find? This multicenter study followed 1,688 individuals with hereditary or familial pancreatic cancer risk across 25 centers. Presumed IPMNs were identified in 29.4% of...

04

Pancreatic Enzymes Do Not Relieve Chronic Pancreatitis Pain: Gut | September 2026

What Did the Study Find? Could non-enteric-coated pancreatic enzymes relieve pain even though earlier enzyme studies have been unconvincing? Investigators at two centres randomised 107 adults with chronic...

05

Pancreatic Cancer Care Is Becoming Multimodal—Now It Needs to Become Integrated: The Lancet Gastroenterology & Hepatology | 2026

What Does This Commentary Highlight? Modern PDAC management increasingly combines systemic therapy, surgery, molecular profiling and surveillance, but these components often remain disconnected. Early systemic therapy is increasingly...

06

Olomorasib Receives FDA Breakthrough Therapy Designation in KRAS G12C–Mutant Pancreatic Cancer: FDA / Oncology Update | August 2026

Introduction: KRAS mutations drive the vast majority of pancreatic cancers, but KRAS G12C represents only about 1–2% of cases. This small molecular subgroup is increasingly actionable. The FDA...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer